Suchergebnisse - "Burgalassi, Andrea"

PubPharm (7)

1

Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine : A Prospective Multicenter Cohort Study

enthalten in: CNS drugs | 2023

von Caponnetto, V. | Russo, A. | Silvestro, M. | +42

2

Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study

enthalten in: CNS drugs | 2023

von Caponnetto, V. | Russo, A. | Silvestro, M. | +30

3

Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)

enthalten in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2023

von Onofri, A. | Iannone, L. | Granato, A. | +30

4

Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria : A retrospective cohort study

enthalten in: Cephalalgia : an international journal of headache | 2023

von Iannone, L. | Burgalassi, A. | Vigani, G. | +4

5

Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)

enthalten in: Neurological sciences | 2023

von Onofri, A. | Iannone, L. | Granato, A. | +29

6

Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)

enthalten in: Neurological sciences | 2023

von Onofri, A. | Iannone, L. | Granato, A. | +29

7

Adverse drug reactions in SARS-CoV-2 hospitalised patients : a case-series with a focus on drug-drug interactions

enthalten in: Internal and emergency medicine | 2021

von Crescioli, G. | Brilli, V. | Lanzi, C. | +8

CommentIn: Intern Emerg Med. 2021 Apr;16(3):797-798. - PMID 33517559

1
[1]